Please provide your email address to receive an email when new articles are posted on . Among systemic rheumatic diseases, the risk for opportunistic infection is highest among patients with ...

This page lists all known medications that could potentially lead to 'Polymyositis' as a side effect. It's important to note that mild side effects are quite common with medications. The medication(s) ...

Q: Which doctor should I consult for polymyositis? A: A neurologist or rheumatologist must be consulted first and additional expertise may be required from a pulmonologist, physiotherapist and speech ...

Q: I started to develop weakness that made it hard for me to get out of a chair. My doctor thinks it may be polymyositis and referred me to a specialist. What is this disease? A: Polymyositis (PM) is ...

PF1801 is a novel long-acting glucagon-like peptide-1 receptor agonist. The Food and Drug Administration (FDA) has granted Orphan Drug designation to PF1801 for the treatment of polymyositis.

Belonging to the same group of autoimmune diseases, both dermatomyositis and polymyositis cause muscle inflammation and weakness. But dermatomyositis also affects your skin and is more likely to ...

The alternative text for this image may have been generated using AI. New research from Tokyo, Japan could help clarify the role of proinflammatory mediators in the pathogenesis of chronic ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Many patients who might have previously been diagnosed with polymyositis are now being treated for ...

Inflammatory myopathies are the largest group of potentially treatable myopathies in children and adults. They constitute a heterogeneous group of disorders that are best classified, on the basis of ...

Nearly one-third of PM/DM patients are readmitted within 180 days. Common causes of readmission include PM exacerbations and sepsis. Female patients, obese patients, patients with comorbid conditions, ...

We report two cases of chronic GVHD presenting with polymyositis manifestations 13 and 19 months after allogeneic hematopoietic stem cell transplant, successfully treated with corticosteroids and ...